Topical application of sphingosine 1-phosphate receptor 1 prolongs corneal graft survival in mice

Zhu,Jing; Liu,Yong; Huang,Yifei

doi:10.3892/mmr.2015.3230

Topical application of sphingosine 1-phosphate receptor 1 prolongs corneal graft survival in mice

Authors:
- Jing Zhu
- Yong Liu
- Yifei Huang
View Affiliations

Affiliations: Department of Ophthalmology, The First Affiliated Hospital of the Chinese PLA General Hospital, Beijing 100038, P.R. China, Department of Ophthalmology, Chinese PLA Air Force General Hospital, Beijing 100038, P.R. China, Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: January 20, 2015 https://doi.org/10.3892/mmr.2015.3230
Pages: 3800-3807

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of topical application of sphingosine 1‑phosphate receptor 1 (S1P1) on allogeneic corneal transplantation in mice. A total of 45 BALB/c mice received corneal grafts from C57BL/6 donors. The recipients were randomly divided into three groups and treated with eye drops containing 0.5% S1P1, 1% cyclosporine A or saline as a negative control. The serum levels of interleukin (IL)‑2, IL‑10, tumor growth factor (TGF)‑β1 and interferon (IFN)‑γ were measured by ELISA. The numbers of CD4+ T cell and T‑regulatory (Treg) cell phenotypes were measured by flow cytometry. The cytokine mRNA expression was analyzed by quantitative polymerase chain reaction. The results demonstrated that corneal graft survival was prolonged in the S1P1 group [mean survival time (MST), 24.11±1.58 days], and 1% cyclosporine A (MST, 25.0±1.91 days) compared with the controls (MST, 13.44±0.48 days; P<0.01). S1P1 and cyclosporine A decreased CD4+ T‑cell levels (P<0.05) in the peripheral blood compared with those of the controls. However, an increase of CD4+ T cells in the spleen was noted in the S1P1 group (P<0.05) and Treg cells were also increased in the cervical lymph nodes in the S1P1 group (P<0.01). TGF‑β1 mRNA transcription in the corneal grafts increased following treatment with S1P1 (P<0.05) and TGF‑β1 in the serum following treatment with S1P1 also increased (P<0.01). In conclusion, S1P1 had a significant effect in corneal allograft rejection inhibition.

View Figures

View References

1	Oliva MS, Schottman T and Gulati M: Turning the tide of corneal blindness. Indian J Ophthalmo. 160:423–427. 2012. View Article : Google Scholar
2	Streilein JW: New thoughts on the immunology of corneal transplantation. Eye. 17:943–948. 2003. View Article : Google Scholar : PubMed/NCBI
3	Williams KA, Lowe M, Bartlett C, Kelly TL and Coster DJ: Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation. 86:1720–1724. 2008. View Article : Google Scholar : PubMed/NCBI
4	Maguire MG, Stark WJ, Gottsch JD, et al: Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 101:1536–1547. 1994. View Article : Google Scholar : PubMed/NCBI
5	Panda A, Vanathi M, Kumar A, Dash Y and Priya S: Corneal graft rejection. Surv Ophthalmol. 52:375–396. 2007. View Article : Google Scholar : PubMed/NCBI
6	Niederkorn JY: Immune mechanisms of corneal allograft rejection. Curr Eye Res. 32:1005–1016. 2007. View Article : Google Scholar : PubMed/NCBI
7	Chauhan SK, Saban DR, Lee HK and Dana R: Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol. 182:148–153. 2009. View Article : Google Scholar :
8	Cunnusamy K, Paunicka K, Reyes N, et al: Two different regulatory T cell populations that promote corneal allograft survival. Invest Ophthalmol Vis Sci. 51:6566–6574. 2010. View Article : Google Scholar : PubMed/NCBI
9	Inoue K, Kimura C, Amano S, et al: Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol. 45:378–382. 2001. View Article : Google Scholar : PubMed/NCBI
10	Shimazaki J, Den S, Omoto M, et al: Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol. 152:33–39. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhang ZY, Zhang Z, Zug C, et al: AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis. J Neuroimmunol. 216:59–65. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hanessian S, Charron G, Billich A and Guerini D: Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett. 17:491–494. 2007. View Article : Google Scholar
13	Brinkmann V, Davis MD, Heise CE, et al: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 277:21453–21457. 2002. View Article : Google Scholar : PubMed/NCBI
14	Pan S, Mi Y, Pally C, et al: A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 13:1227–1234. 2006. View Article : Google Scholar : PubMed/NCBI
15	Sedláková K, Muckersie E, Robertson M, Filipec M and Forrester JV: FTY720 in corneal concordant xenotransplantation. Transplantation. 79:297–303. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mayer K, Birnbaum F, Reinhard T, et al: FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol. 88:915–919. 2004. View Article : Google Scholar : PubMed/NCBI
17	Zhang EP, Müller A, Ignatius R and Hoffmann F: Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice. Transplantation. 76:1511–1513. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cohen JA, Barkhof F, Comi G, et al: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362:402–415. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang EP, Schrunder S and Hoffmann F: Orthotopic corneal transplantation in the mouse: a new surgical technique with minimal endothelial cell loss. Graefes Arch Clin Exp Ophthalmol. 234:714–719. 1996. View Article : Google Scholar : PubMed/NCBI
20	Brinkmann V, Cyster JG and Hla T: FYT720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 4:1019–1025. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zhang JL, Sun DJ, Hou CM, et al: CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney. Transpl Immunol. 24:17–25. 2010. View Article : Google Scholar : PubMed/NCBI
22	Xie Y, Sun HX and Li D: Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine. 27:757–764. 2009. View Article : Google Scholar
23	Küchle M, Cursiefen C, Nguyen NX, et al: Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol. 240:580–584. 2002. View Article : Google Scholar : PubMed/NCBI
24	Xie L, Shi W, Wang Z, Bei J and Wang S: Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea. 20:748–752. 2001. View Article : Google Scholar : PubMed/NCBI
25	Bourges JL, Lallemand F, Agla E, et al: Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis. 12:1461–1466. 2006.PubMed/NCBI
26	Sinha R, Jhanji V, Verma K, et al: Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 248:1167–1172. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ziaei M and Manzouri B: Topical cyclosporine in corneal transplantation. Cornea. 29:Oct 29–2014.(Epub ahead of print).
28	Unal M and Yucel I: Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 92:1411–1414. 2008. View Article : Google Scholar : PubMed/NCBI
29	Poon A, Constantinou M, Lamoureux E and Taylor HR: Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 36:415–421. 2008.PubMed/NCBI
30	Alalwani H, Omer Saleh B, Rocher N, et al: Advantages and limits of multiple grafts (third keratoplasty) under local cyclosporin 2%. J Fr Ophtalmol. 33:710–714. 2010.(In French). View Article : Google Scholar : PubMed/NCBI
31	Wang GY, Yang Y, Li H, et al: Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4(+) CD25(+) Foxp3(+) regulatory T cell expansion. Hepatol Res. 42:192–202. 2012. View Article : Google Scholar
32	Lu L, Ma J, Wang X, et al: Synergistic effect of TGF-beta superfamily members on the induction of Foxp3⁺ Treg. Eur J Immunol. 40:142–152. 2010. View Article : Google Scholar :
33	Hofmann U, Hu K, Walter F, et al: Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol. 160:1243–1251. 2010. View Article : Google Scholar : PubMed/NCBI
34	Stanojlovic S, Schlickeiser S, Appelt C, et al: Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol. 248:1447–1456. 2010. View Article : Google Scholar : PubMed/NCBI
35	Matsuoka K, Kim HT, McDonough S, et al: Altered regulatory T cell homeostasis in patients with CD4⁺ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 120:1479–1493. 2010. View Article : Google Scholar : PubMed/NCBI
36	Schneider MA, Meingassner JG, Lipp M, Moore HD and Rot A: CCR7 is required for the in vivo function of CD4⁺CD25⁺ regulatory T cells. J Exp Med. 204:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
37	Commodaro AG, Peron JP, Lopes CT, et al: Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci. 51:2568–74. 2010. View Article : Google Scholar
38	Sehrawat S and Rouse BT: Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3⁺ regulators. J Immunol. 180:7636–7647. 2008. View Article : Google Scholar : PubMed/NCBI
39	Bocian K, Borysowski J, Wierzbicki P, et al: Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4⁺CD25⁺ Tregs. Nephrol Dial Transplant. 25:710–717. 2010. View Article : Google Scholar
40	Zeiser R, Nguyen VH, Beilhack A, et al: Inhibition of CD4⁺CD25⁺ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 108:390–399. 2006. View Article : Google Scholar : PubMed/NCBI
41	Yamagami S, Dana MR and Tsuru T: Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea. 21:405–409. 2002. View Article : Google Scholar : PubMed/NCBI
42	Kobayashi T, Momoi Y and Iwasaki T: Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci. 69:887–892. 2007. View Article : Google Scholar : PubMed/NCBI
43	Li J, Ballim D, Rodríguez M, et al: The anti-proliferative function of the TGF-β1 signalling pathwayinvolves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem. Nov 4–2014.(Epub ahead of print).